Evidence map›Paper›PMID 35985830›Full record

ArticleNeurology2022

Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.

J Nicholas Brenton, Brian Florenzo, Hitoshi Koshiya, Seulgi Min, Emma Woolbright, Rachael Coleman, Shanshan Chen, Myla Goldman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Sensors in Multiple Sclerosis.Current neurology and neuroscience reports · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Nicholas BrentonFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond. jnb8h@virginia.edu.ORCID 0000-0001-9432-1347
Brian FlorenzoFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Hitoshi KoshiyaFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Seulgi MinFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Emma WoolbrightFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Rachael ColemanFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Shanshan ChenFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.
Myla GoldmanFrom the Division of Pediatric Neurology (J.N.B., S.M., E.W., R.C.), Department of Neurology, and School of Medicine (B.F., H.K.), University of Virginia, Charlottesville; and Departments of Biostatistics (S.C.) and Neurology (M.G.), Virginia Commonwealth University, Richmond.ORCID 0000-0002-5675-945X

Funding

Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple SclerosisK23NS116225 · NINDS · UNIVERSITY OF VIRGINIA · PI BRENTON, JAMES NICHOLAS · 2021 to 2025
$962k
NINDS NIH HHS K23 NS116225
6 · The paper itself

Abstract

BACKGROUND AND

objectivesDespite low levels of disability, youth with pediatric-onset multiple sclerosis (POMS) engage in less physical activity compared with peers. The contribution of walking capacity, endurance, behavior, and MS comorbidities remains relatively undefined and may provide valuable insights into the limitations toward physical activity in youth with MS. The primary objective of this study was to investigate differences in walking capacity, endurance, and real-world behaviors of daily activity between youth with POMS and controls.

methodsYouth diagnosed with MS prior to 18 years and aged 21 years or younger were recruited in addition to healthy controls. Participants completed questionnaires to quantify fatigue, depression, and physical activity levels and the timed 2- and 6-minute walk (6MW) as an assessment of walking capacity and endurance. Participants completed questionnaires to quantify fatigue, depression, and physical activity levels. Participants also completed the timed 2- and 6-minute walk (6MW) as an assessment of walking capacity and endurance and were sent home with a waist-worn accelerometer to assess real-world walking behavior.

resultsForty-five patients with POMS and 85 control participants were enrolled. The POMS cohort had a mean age of 16.9 ± 2.7 years, with a mean disease duration of 2.8 ± 2.6 years. A greater proportion of the POMS cohort was overweight/obese compared with controls (75% vs 33%). Participants with MS walked a significantly shorter distance in 6 minutes compared with controls (1,848 feet vs 2,134 feet, DISCUSSION: Youth with POMS exhibit slower 6MW performance and less daily engagement in moderate-to-vigorous physical activity, suggesting limitations in functional walking capacity, endurance, and daily activity behavior. Limitations in walking endurance and capacity are most prominent in those youth who are overweight/obese and living with MS. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that, compared with healthy controls, patients with POMS walk shorter distances on the 6MW test, are less able to accelerate to peak speed at the end of the test, and are less physically active.

Indexed as

Multiple SclerosisAdolescentFatigueHumansObesityOverweightWalkingYoung Adult

Identifiers

PMID35985830
PMCPMC9651457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.